Ginkgo Bioworks Holdings (DNA) — Cash Flow-to-Debt Ratio
Ginkgo Bioworks Holdings (DNA) has a Cash Flow-to-Debt Ratio of -0.08x as of March 2026, meaning its operating cash flow of $-46.43 Million could theoretically repay 0% of its total liabilities ($589.92 Million) in one year. See DNA net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ginkgo Bioworks Holdings Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Ginkgo Bioworks Holdings across 7 annual periods. Also explore DNA net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Ginkgo Bioworks Holdings (2019–2025)
Year-by-year debt coverage analysis for Ginkgo Bioworks Holdings. For market capitalisation and broader financial context, see market cap of Ginkgo Bioworks Holdings.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.28x | $-171.06 Million | $611.11 Million | ▲ +42.1% |
| 2024 | -0.48x | $-319.58 Million | $661.39 Million | ▲ +7.1% |
| 2023 | -0.52x | $-295.50 Million | $568.19 Million | ▼ -65.6% |
| 2022 | -0.31x | $-252.20 Million | $803.04 Million | ▲ +37.7% |
| 2021 | -0.50x | $-253.82 Million | $503.61 Million | ▲ +23.9% |
| 2020 | -0.66x | $-135.83 Million | $205.10 Million | ▼ -189.8% |
| 2019 | -0.23x | $-44.66 Million | $195.47 Million | — |